Abstract:Abstract In 1806, French physician Baron Jean-Louis Alibert treated a 56-year-old man with a desquamating rash and skin tumours. Alibert considered this to be a variant of yaws. In 1829 Alibert named the condition mycosis fungoides (MF), meaning ‘mushroom-like fungal disease’. Over 100 years later, French dermatologist Albert Sézary published papers from 1938 to 1949 detailing a mysterious disease that caused erythroderma and ‘cellules monstrueuses’, describing cutaneous ‘monster cells’. In 1961, these clinical findings were collated together into ‘Sézary syndrome’. Over this time there was widespread confusion between these conditions, fungal infections and yaws. In the 1870s English dermatologist William Tilbury Fox published a dermatology atlas detailing cases similar to what we know now as MF, with the name ‘fibroma fungoides’. The atlas described MF as a type of fungus, before giving a description of yaws and painting a clinical picture that differed from that of a lymphoma. In 1975, Pierre-Antoine-Ernest Bazin and associates in suggested the classification system and term we now recognize as cutaneous T-cell lymphoma (CTCL). Neoplastic cells have been thought to arise from chronic activation of T cells via antigen-presenting cells, yet the antigen to trigger this response remains unknown. Several potential bacterial, viral, fungal and iatrogenic causes have been studied, but no reliable triggers have been discovered. In 2018, the World Health Organization and European Organisation for Research and Treatment of Cancer officially recognized four types of MF. These are the classic Alibert–Bazin type (representing 88.6% of cases) and its three subtypes; folliculotropic MF (11.4%), Pagetoid reticulosis, and granulomatous slack skin (both with a combined 1% prevalence). CTCL has an incidence of approximately 0.2–0.6 per 100 000 person-years, with MF being the most common subtype. MF is twice as common in male as in female patients. It is twice as common in those of Black ethnic background than in White and Asian ethnicities. Development of immunohistochemistry and polymerase chain reaction for the T-cell receptor gene in the 1980s improved the diagnosis of CTCL. However, diagnosis of MF remains challenging due to its heterogeneous presentation, often mimicking inflammatory dermatoses. Advanced disease therapies have evolved from cytotoxic chemotherapy in the 1970s to novel monoclonal antibodies such as mogamulizumab, targeting proteins on T-cell lymphoma cells (CCR4). Reflection on the past two centuries from Alibert to mogamulizumab offers insight into the challenges that accompany the aetiology, diagnosis, classification and management of MF.

Urticarial mycosis fungoides: A distinctive presentation with blood involvement and a peculiar immunophenotype

Ichthyosiform Mycosis Fungoides with Alopecia and Atypical Membranous Nephropathy

Mimicry unveiled: The challenging diagnosis of pigmented purpura-like mycosis fungoides initially misdiagnosed as pigmented purpura

When mycosis fungoides seems not to be within the spectrum of clinical and histopathological differential diagnoses

Null T‐cell phenotype mycosis fungoides with aberrant CD20 and CD56 expression: A diagnostic dilemma

Unveiling the Rarity: CD20 Expression in Mycosis Fungoides and Its Clinical Significance

A Man with Worsening Scaling Plaques and a New Onset Large Draining Ulcerated Tumor

Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management

Photosensitive presentation of aggressive mycosis fungoides mimicking systemic lupus erythematosus

H03 (P068) A history of mycosis fungoides: from Alibert to mogamulizumab

P068 A history of mycosis fungoides: from Alibert to mogamulizumab

Mycosis Fungoides: A Multidisciplinary Team Approach.

Correction To: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: an International Expert Panel Discussion.

Interstitial mycosis fungoides: A rare presentation of mycosis fungoides with overlapping granulomatous and folliculotropic features

Clinical Features and Treatment of Unilesional Mycosis Fungoides

[Bullous mycosis fungoides-clinical indicator for an aggressive course of disease]

Primary cutaneous, epidermotropic mycosis fungoides-like presentation: critical appraisal and description of two novel cases, broadening the spectrum of ALK+ T-cell lymphoma

A case report of refractory advanced-stage mycosis fungoides: successful treatment and improved patient quality of life with mogamulizumab

[Simultaneous presentation of bullous pemphigoid and mycosis fungoides]

Systemic involvement in mycosis fungoides

Pigmented purpura dermatosis-like mycosis fungoides: four case reports and a review of published cases